



IPO Note

PARAS HEALTHCARE LIMITED

OCT 21th, 2026



Oct 21st, 2026

Details of the Issue

Price Band	₹ 600 - ₹ 693
Issue Size	₹ 1,450 Cr
Market Cap	₹ 7,498.34 Cr
Face Value	₹ 1
Bid Lot	21
Listing on	BSE,NSE
Investment Range	₹ 12,600 - ₹ 14,553

Important Indicative Dates (2026)

Opening	21 - Oct
Closing	23 - oct
Basis of Allotment	26 - Oct
Refund Initiation	27 - Oct
Credit to Demat	27 - Oct
Listing Date	28 - Oct

Lead Manager

BofA Securities India Ltd
JM Financial Ltd
Nuvama Wealth Management Ltd

Offer Details

Offer Size	₹ 1,450 Cr
Fresh Issue	₹ 500 Cr
OFS	₹ 950 Cr

Type	In Rs Cr	No of Shares (Mn)		% of Issue
		Upper	Lower	
QIB	1,088	15.69	16.48	75
NII	218	3.14	3.30	15
Retail	145	2.09	2.20	10
Em-ploy.	-	-	-	-
Total	1,450	20.92	21.97	100

[Invest Now](#)Company Profile

Paras Healthcare Limited is a clinical specialty-led hospital chain operating eight hospitals with 2,211 beds across North India, Bihar, and Jharkhand under the Paras Health brand, offering tertiary and quaternary healthcare services across key CONGOR specialties, which contributed 75.30% of FY26 revenue. With over 20 years of operating experience, the company follows a balanced growth strategy across mature, emerging, and new hospitals, supported by advanced clinical infrastructure and standardized care protocols. It plans to expand capacity to 3,011 beds by March 2028 through a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana. As of March 31, 2026, the company had 4,670 employees, including 1,084 doctors and 1,937 nurses, supporting its clinical operations and expansion plans.

GEPL's Insights & Investment Thesis:

- Paras Healthcare Limited is a clinical specialty-led hospital chain operating across Tier-2 and Tier-3 markets with a strong presence in the North India region.
- The company generated approximately 41% of its revenue from government schemes and PSU patients in FY26. This creates risk if there are any changes in government healthcare policies, delays in reimbursements, which could impact cash flows significantly.
- Based on FY26 earnings, the issue is priced at a EV/EBITDA of 24x, which appears fairly valued. The company is pursuing a calibrated expansion strategy, reported healthy financial performance, however, faces the risk of dependence on government schemes, evolving regulatory pharma prices, and large contingent liability. Therefore, we recommend an **"Avoid"** rating for the issue.

Business Highlights & Services

Paras Healthcare has established a strong regional presence across North India, Bihar and Jharkhand, operating eight hospitals with 2,211 beds across five states and one union territory as of June 30, 2026. Since establishing its first hospital in Gurugram in 2006, the company has expanded its capacity from 200 beds to 2,211 beds, benefiting from early entry into select markets and differentiated positioning in locations such as Gurugram, Patna, Panchkula and Srinagar. Its expansion strategy focuses on underserved markets with large catchment populations and growing demand for specialized healthcare. The planned 300-bed hospital in Gurugram and 500-bed hospital in Ludhiana are expected to increase total capacity to 3,011 beds by March 2028, representing approximately 36% growth over the existing bed capacity. This expansion, supported by an established regional brand and rising demand for tertiary and quaternary care, provides a platform for long-term revenue growth. Paras Healthcare maintains a strong focus on cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and sports injury, and renal sciences (CONGOR), which contributed 75.30% of revenue in FY26. The company is strengthening its high-acuity treatment capabilities through investments in robotic surgery, radiation oncology, PET-CT facilities, advanced neurosurgery and organ transplant programs. It has expanded its ICU capacity from 425 beds in March 2024 to 559 beds in June 2026, enhancing its ability to manage complex and critical cases. The commissioning of LINAC facilities at Ranchi and Udaipur, a second LINAC and PET-CT facility at Patna, and robotic surgery programs across Patna, Panchkula and Kanpur further strengthen its clinical offerings.




These specialized services can support higher ARPOB, improve patient realizations and enhance the company's competitive positioning, while the planned rollout of additional clinical programs provides scope to deepen specialty penetration across its network.

Paras Healthcare combines an experienced medical workforce with advanced infrastructure, standardized clinical protocols and digital systems to support patient outcomes and operating efficiency. As of June 30, 2026, the company employed 1,084 doctors and 1,937 nurses, including nationally recognized clinicians, while seven of its eight hospitals were accredited by the NABH. Its patient satisfaction score of 90.60 and net promoter score of 93.31 as of March 31, 2026, reflect its focus on patient experience and service quality. Furthermore, its cloud-based hospital information systems, electronic health records, centralized patient engagement platforms and business intelligence tools support data-driven decision-making, clinical coordination and cost control. The company also follows a flexible operating model comprising owned, leased, revenue-sharing and public-private partnership hospitals, enabling calibrated capital deployment, lower upfront investment in select markets and disciplined expansion. These capabilities, combined with its established brand and standardized care delivery, can support improved hospital utilization, operating leverage and scalable growth as newer facilities mature. The Indian healthcare delivery market is projected to grow at a CAGR of 10-12% between FY25 and FY30, providing a favourable growth outlook, while the company plans to expand its capacity to 3,011 beds by March 2028. Its focus on high acuity CONGOR specialties, which contributed 75.30% of FY26 revenue, along with investments in robotic surgery, LINACs, PET-CT and organ transplantation, can support higher patient realizations and ARPOB. Strong patient satisfaction, NABH accreditation across seven hospitals, experienced clinicians and digital integration further strengthen its competitive positioning, while a flexible hospital operating model supports disciplined capital deployment and potential operating leverage as newer facilities mature.

The company is pursuing a calibrated expansion strategy through brownfield expansion, greenfield hospital development and selective acquisitions, targeting underserved markets with low hospital bed density and limited access to advanced tertiary and quaternary healthcare. The company aims to increase its total bed capacity from 2,211 beds as of June 30, 2026, to 3,011 beds by March 2028, supported by the planned 300-bed Gurugram II Hospital and 500-bed Ludhiana Hospital. It is also evaluating expansion opportunities in markets such as the National Capital Region, Meerut and Agra, while adding capacity at existing facilities, including Patna and Panchkula. In parallel, the company is focused on improving the performance of its emerging hospitals in Ranchi and Udaipur and ramping up its newer hospitals in Srinagar and Kanpur through clinician recruitment, introduction of additional specialties, outreach clinics, cancer screening initiatives and expanded empanelment with government healthcare schemes and insurance providers. Paras Healthcare is further strengthening its high-acuity CONGOR specialties through investments in oncology, robotic surgery, organ transplantation, advanced diagnostic equipment and other complex clinical programs, which can improve patient acquisition, treatment realizations and ARPOB. Its DNB training programs across 4 hospitals, covering 14 specialties with an annual training capacity of 60 students, also support the development of a qualified clinical workforce. Additionally, investments in digital platforms, revenue cycle management, standardized treatment protocols, centralized procurement, optimized staffing and reduced ALOS are expected to improve bed utilization, streamline insurance claims and control operating costs. Collectively, these initiatives provide opportunities for sustained revenue growth and operating leverage as newer hospitals mature and existing facilities improve occupancy and specialty mix; however, the realization of these benefits will depend on timely execution of expansion projects, effective capacity utilization, clinician availability and disciplined capital deployment.

Bed & New Hospital Addition Trend





KIP's of the business

Particular	Units	Q1FY27	Q1FY26	FY26	FY25	FY24
No of Hospital	Number	8	8	8	8	8
Total bed capacity	Number	2,211	2,135	2,211	2,135	2,135
No of ICU beds	Number	559	466	559	466	425
Operational Beds	Number	1,502	1,465	1,502	1,465	1,332
Bed Occupancy rate	%	69.72	56.75	61.75	50.78	52.46
ARPOB	INR Per days	49,352	48,664	47,398	48,089	44,306
ALOS	In days	2.77	2.87	2.93	2.89	3.14
In-Patient volume	Number	34,354	26,362	1,15,496	93,170	81,047
Out-Patient volume	Number	2,25,735	1,78,977	7,78,707	6,38,193	5,69,139
Capex per bed	INR in Mn	7.70	7.46	7.63	7.18	5.84
No of surgeries	Number	11,112	9,260	39,687	33,072	30,219


Specialty Mix and Payor Mix

Particular	Q1FY27	Q1FY26	FY26	FY25	FY24
Cardiac Sciences	13.31	12.11	12.78	11.72	13.24
Oncology	19.43	23.00	21.63	19.86	18.90
Neuro sciences	12.50	13.43	13.03	15.13	15.14
Orthopaedics and sports injury	12.13	11.64	10.75	10.69	12.30
Gastro sciences	8.24	7.50	8.30	6.46	5.11
Renal sciences	8.74	7.62	8.21	8.06	7.65
Other	25.65	24.70	25.30	28.08	27.66


Particular	Q1FY27	Q1FY26	FY26	FY25	FY24
Self Pay	31.30	34.27	33.88	41.01	40.63
Insurance/TPA	25.07	27.67	24.84	28.08	29.61
Govt Schemes	43.63	38.06	41.28	30.91	29.76

Industry Outlook

Segmentation of the Indian healthcare delivery market, Fiscal 2020 to 2030P (₹ trillion)



Region-wise healthcare delivery market share in India, Fiscal 2020 to 2030P (₹ trillion)





Peers comparison

Name of the company	Face Value (₹)	Total Revenue (₹ Cr)	EPS	NAV (₹)	EV/EBITDA (x)	RoNW(%)
Paras Healthcare Ltd	1	1606	4.34	39.11	NA	12.98
Peers Group						
Aster DM Quality Care Ltd	10	4,643	7.52	88.32	40.73	9.7
Apollo Hospital Enterprises Ltd	5	25,229	134	657	32.59	21.95
Fortis Healthcare Ltd	10	9,128	13.80	131	28.88	11.08
Global healthcare Ltd	2	4,410	20.66	147	34.03	15.15
Jupiter Lifeline Hospital Ltd	2	1,500	5.92	47.10	25.79	13.41
KIMS	2	3,905	6.03	56.17	40.64	11.01
Manipal Health Enterprises Ltd	2	10,936	7.67	63.26	36.89	12.37
Max Healthcare Institute Ltd	10	10,065	14.76	109	35.69	14.33
Narayana Healthcare Ltd	10	7,896	39.67	222	22.67	19.74
Yatharth Hospital and Trauma Care services Ltd	10	1,207	18.20	184	33.12	10.36

Company's Competitive Strength

- One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First Mover Advantage and a Well Recognized Brand.
- Strong Focus on Tertiary and Quaternary Care with High Contribution from CONGOR Specialties.
- Capital-Efficient and Flexible Operating Model with Disciplined Expansion.
- Delivering High-Quality Clinical Care Through Renowned Clinicians, Supported with Modern Equipment.
- Digital Technology Enabling Clinical Effectiveness, Patient Experience and Operational Efficiencies.
- Doctor Led Professional Management Team with Proven Execution Capabilities.

Key Strategies Implemented by Company

- Scale Operations at the Hospitals .
- Continue to Expand the Network of Hospitals in North India Whitespaces.
- Expand into New and High-End Clinical Programs at the Hospitals Supported by Advanced Technology.
- Continue to Attract and Retain Qualified and Experienced Clinicians.
- Improve Operational Efficiencies and Patient Experience.

Particular (INR in Cr)	FY26	FY25	FY24
Equity Capital	10	10	10
Reserves and Surplus	385	271	329
Net Worth	395	280	339
Revenue	1,606	1,294	1,129
Growth (%)	24%	15%	
EBITDA	336	156	154
EBITDAM (%)	20.90%	12.09%	13.68%
PAT	44	-58	-15
PATM (%)	2.7%	-4.5%	-1.4%
ROE (%)	13.0%	-18.7%	-8.3%



Notes

GEPL Capital Pvt. Ltd

Head Office: D-21/22 Dhanraj Mahal, CSM Marg, Colaba, Mumbai 400001

Reg. Office: 922-C, P.J. Towers, Dalal Street, Fort, Mumbai 400001

Research Analyst – Mr. Vidnyan Sawant | + 022-6618 27687 | vidnyansawant@geplcapital.com

Disclaimer: This report has been prepared by GEPL Capital Private Limited ("GEPL Capital "). GEPL Capital is regulated by the Securities and Exchange Board of India. This report does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy, recommendation or any other content contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. All investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by the recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of GEPL Capital as a result of using different assumptions and criteria. GEPL Capital is under no obligation to update or keep current the information contained herein. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect GEPL Capital's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by GEPL Capital or any other source may yield substantially different results. GEPL Capital makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. Further, GEPL Capital assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Neither GEPL Capital nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. In no event shall GEPL Capital be liable for any direct, special indirect or consequential damages, or any other damages of any kind, including but not limited to loss of use, loss of profits, or loss of data, whether in an action in contract, tort (including but not limited to negligence), or otherwise, arising out of or in any way connected with the use of this report or the materials contained in, or accessed through, this report. GEPL Capital and its affiliates and/or their officers, directors and employees may have similar or an opposite position in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). The disclosures contained in the reports produced by GEPL Capital shall be strictly governed by and construed in accordance with Indian law. GEPL Capital specifically prohibits the